Qurient Co., Ltd. (KOSDAQ:115180)

Market Cap	1.30T +665.5%
Revenue (ttm)	8.28B -5.4%
Net Income	-24.18B
EPS	-690.86
Shares Out	40.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,438
Average Volume	260,693
Open	32,300
Previous Close	33,700
Day's Range	31,050 - 32,800
52-Week Range	5,640 - 39,950
Beta	0.82
RSI	48.38
Earnings Date	Mar 17, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.